Abstract Library

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4410 NETest can predict the tumour burden in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are rare malignancies characterised by slow growth and a lack of reliable biomarkers for predicting tumour burden, treatment response, and prognosis.

Conference:

Presenting Author:

Authors: You T, Zhou N, Tang H, Ying J, Wang C,

Keywords: NETest, biomarker, NET,

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#3783 Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors

Introduction: Despite progresses in NET management, there are persisting challenges regarding initial diagnosis, treatment response assessment and disease follow-up.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, de Dosso S, Wild D, Siebenhüner A, Voegeli M,

Keywords: transcriptomics, biomarker, NETest, clinical management, NET,

#3756 The clinical utility of NETest in patients with small intestinal neuroendocrine neoplasms (SI-NENs) – A "real-life" study

Introduction: Management of patients with SI-NENs is challenging due to biological heterogeneity. Prognostication can be difficult, mostly due to a lack of reliable biomarkers.

Conference:

Presenting Author:

Authors: Gertner J, Hayes A, Furtado O'Mahony L, Glover T, Karia P,

Keywords: Neuroendocrine neoplasm, small intestine, NETest, tumor growth rate, biomarker,